Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Envoy MedicalCOCH -2.07%6 EV-to-EBITDA is -1.59 as of Sep. 06, 2026. GuruFocus rates COCH with a GF Score™ of 6/100 and a GF Value™ of $0.66 (Fairly Valued). The stock has 6 warning signs investors should review. Among 516 Medical Devices & Instruments companies, Envoy Medical ranks worse than 193798.26% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Envoy Medical's enterprise value is $36.07 Mil.
Envoy Medical's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-22.63 Mil. Therefore, Envoy Medical's EV-to-EBITDA for today is -1.59.
The historical rank and industry rank for Envoy Medical's EV-to-EBITDA or its related term are showing as below:
COCH'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -5.82 Med: -2.21 Max: -0.39
Current: -1.59
During the past 5 years, the highest EV-to-EBITDA of Envoy Medical was -0.39. The lowest was -5.82. And the median was -2.21.
COCH's EV-to-EBITDA is ranked worse than 100% of 516
companies
in the Medical Devices & Instruments industry
Industry Median: 14.3
vs COCH: -1.59
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Envoy Medical's PE Ratio (TTM) for today is calculated as:
Envoy Medical's share price for today is $0.7099.
Envoy Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.760.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Envoy Medical's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Envoy Medical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Envoy Medical EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Envoy Medical's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Envoy Medical's EV-to-EBITDA falls into.
Envoy Medical's current Enterprise Value is $36.07 Mil.
Envoy Medical's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.63 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Envoy Medical (COCH) has a EV-to-EBITDA of -1.59 as of Sep. 06, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Envoy Medical. According to the industry distribution chart, Envoy Medical ranks #999999 out of 516 companies in the Medical Devices & Instruments industry.
Is Envoy Medical's EV-to-EBITDA too high?
Envoy Medical's current EV-to-EBITDA is -1.59. Based on the distribution chart, Envoy Medical ranks #999999 out of 516 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Envoy Medical has a GF Score™ of 6/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Envoy Medical's EV-to-EBITDA compare to XTNT and POSC?
According to the Medical Devices & Instruments industry distribution chart, Envoy Medical ranks #999999 out of 516 companies for EV-to-EBITDA. This places Envoy Medical in the lower half of its industry. The industry median EV-to-EBITDA is 14.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.30, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Envoy Medical. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Envoy Medical's current EV-to-EBITDA is -1.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Envoy Medical stock overvalued right now?
Based on GuruFocus' analysis, Envoy Medical (COCH) is currently considered Fairly Valued. The stock's GF Value™ is $0.66, compared to a current price of $0.71 — trading 7.6% above its estimated fair value. The current EV-to-EBITDA is -1.59. Envoy Medical's overall GF Score™ is 6/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Envoy Medical (COCH), the current EV-to-EBITDA is -1.59 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Envoy Medical (COCH) Overvalued in 2026?
Based on GuruFocus' analysis, Envoy Medical stock appears to be overvalued.
The current stock price of $0.71 is trading 7.6% above its estimated GF Value™ of $0.66.
GuruFocus considers Envoy Medical to be Fairly Valued.
Key valuation signals for COCH:
EV-to-EBITDA: -1.59
GF Value™: $0.66 vs. price of $0.71 (7.6% above fair value)
No single metric tells the full story. See the COCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.
6GF Score
Get the complete analysis for COCH
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COCH has been successfully added to your 
